Ralek
— Editorial Enquiries

Correspondence with the catalogue.

The editorial team reviews enquiries regarding catalogue scope, formulation submission requests, methodology questions, and general correspondence. Submissions are reviewed quarterly. The team does not provide personal nutrition guidance.

Contact Details
Address
57 Westbourne Grove
London W2 4UA
United Kingdom
Telephone
+44 20 3761 9528
Office Hours
Mon — Fri
08:00 – 17:00
Response Times
General correspondence 3–5 working days
Formulation submissions Quarterly review
Methodology enquiries 5–7 working days
Find Us
Formulation Submissions

What a submission should include.

Required

Specification Sheet

A full ingredient specification sheet listing every compound by INCI or IUPAC name, quantity per serving in mg or mcg, and percentage of UK Reference Nutrient Intake where applicable.

Required

Sourcing Documentation

Documentation indicating region of origin and supplier for each active ingredient. Vague descriptions such as “natural sources” are not accepted as sufficient sourcing information.

Preferred

Certificate of Composition

An independent batch analysis certificate from a third-party facility. Submissions with verification documentation are prioritised in the quarterly review queue ahead of unverified entries.

Contact FAQ

Common enquiry questions.

No. The Ralek catalogue is an informational reference, not a personal advisory service. The editorial team does not respond to individual nutrition enquiries or provide guidance on which supplements to take. For personal dietary advice, we recommend speaking with a qualified wellness or nutrition professional.

Yes, via the contact form above with enquiry type set to “Formulation Submission”. Include a specification sheet and sourcing documentation at minimum. Submissions without full documentation are not reviewed. Results of quarterly reviews are not shared individually — accepted entries appear in the catalogue without prior notice to the submitter.

Enquiries seeking paid placement, sponsorship, or commercial arrangement of any kind are not responded to. Formulators who make commercial approaches to the editorial team are noted and excluded from the quarterly submission review permanently.